With the new Trump administration taking office, significant policy shifts are on the horizon, particularly for the manufacturing sector. Join Foley & Lardner LLP and In-House Connect on February 26 for a half-day webinar full of insights regarding policy shifts, supply chain, tariffs, international trade laws, and more.
This webinar is broken up into four programs. To learn more about each program and to access the recordings, click the links below:
- Tax, Trade, and Policy Changes Under the New Trump Administration: What to Expect and How to Prepare
- Promo code: IHCFOLEYSUMMIT
- Navigating Supply Chain Contracting in a Volatile Global Landscape
- Promo code: IHCFOLEYSUMMIT2
- International Trade and Manufacturing in Mexico under the New Trump Administration: What to Expect and How to Prepare
- Promo code: IHCFOLEYSUMMIT3
- Managing Import Risks Under the New Trump Administration: What to Expect and How to Prepare
- Promo code: IHCFOLEYSUMMIT4
People
Related Insights
December 4, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
December 4, 2025
Foley Viewpoints
Foley Event Key Takeaways- Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shift
Foley & Lardner, Protiviti and SS&C Intralinks recently hosted an event in Foley’s Silicon Valley office at Palo Alto Center. Moderated by Foley partner Louis Lehot, the session titled "Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shifts," brought together industry leaders: JD Fay (ex-CFO, Matterport, de-SPAC’d and then sold to CoStar Group), Dan Angus (Managing Director, Nasdaq), and Andrea Vardaro Thomas (Managing Director, Protiviti). Their combined experience provided a roadmap for companies facing the volatile and rapidly shifting capital markets of 2026.
December 4, 2025
Foley Viewpoints
FDA Guidance on Biosimilars Highlights Glycosylation Profiling and Increases the Strategic Value of Patents Covering Antibodies Defined by Glycosylation
FDA’s September 2025 guidance requires detailed characterization of posttranslational modifications (PTMs), particularly glycosylation,…